Elanco Animal Health Reports Q3 2026 Revenue Growth and Debt Reduction
Elanco Animal Health (ELAN) reported strong third-quarter 2026 financial results, highlighted by an 11% year-over-year revenue increase to $1.265 billion. The company achieved significant progress in deleveraging its balance sheet, reducing gross debt by $216 million and bringing net leverage below the 3.0x EBITDA threshold ahead of schedule. Growth was driven by a 9% organic constant currency revenue increase and strong performance from innovation products, which generated $328 million. Management emphasized their ability to maintain pricing power without resorting to aggressive discounting, noting a 5% price increase in pet health products alongside rising volumes. Additionally, the 'Elanco Ascend' efficiency program contributed to an adjusted gross margin expansion of three percentage points to 56.1%, with long-term savings targets set through 2030.
Tickers: $ELAN
Topics: animal health debt reduction operating margins revenue growth
Read the full article at Motley Fool
Part of the story Artmarket.com Announces Q3 2026 Revenue Growth and Upcoming Launch of AI-Driven Visual Search Tool (35 articles)